Cargando…

Emerging therapies for breast cancer

HER2 and CDK4/6 are undoubted two most important biological targets for breast cancer. Anti-HER2 treatments enhance objective response and progression-free survival/disease-free survival as well as overall survival. Three CDK4/6 inhibitors consistently improve objective response and progression-free...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Xichun, Huang, Wei, Fan, Minhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410098/ https://www.ncbi.nlm.nih.gov/pubmed/28454587 http://dx.doi.org/10.1186/s13045-017-0466-3

Ejemplares similares

Fenofibrate induces apoptosis of triple-negative breast cancer cells via activation of NF-κB pathway
por: Li, Ting, et al.
Publicado: (2014)

Chemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapy
por: Zhang, Jian, et al.
Publicado: (2015)

Dosing of zoledronic acid with its anti-tumor effects in breast cancer
por: Zhao, Xinmin, et al.
Publicado: (2015)

New and Emerging Targeted Therapies for Advanced Breast Cancer
por: Lau, Kristie H., et al.
Publicado: (2022)

Emerging Roles of Ceramides in Breast Cancer Biology and Therapy
por: Pal, Purab, et al.
Publicado: (2022)

Exosome: emerging biomarker in breast cancer
por: Jia, Yunlu, et al.
Publicado: (2017)

Emerging Targeted Therapies for HER2-Positive Breast Cancer
por: Mercogliano, María Florencia, et al.
Publicado: (2023)

Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2020)

Treating Breast Cancer in the 21st Century: Emerging Biological Therapies
por: Tinoco, Gabriel, et al.
Publicado: (2013)

Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives
por: Kotecki, Nuria, et al.
Publicado: (2018)

Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer
por: El Hachem, Georges, et al.
Publicado: (2019)

Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials
por: Li, Bin, et al.
Publicado: (2023)

Cancer-associated adipocytes: emerging supporters in breast cancer
por: Zhao, Chongru, et al.
Publicado: (2020)

The emerging role of circular RNAs in breast cancer
por: Zhou, Si-ying, et al.
Publicado: (2019)

Pharmacogenomics for Prediction of Cardiovascular Toxicity: Landscape of Emerging Data in Breast Cancer Therapies
por: Altena, Renske, et al.
Publicado: (2022)

An emerging generation of endocrine therapies in breast cancer: a clinical perspective
por: Patel, Rima, et al.
Publicado: (2023)

Nanoparticles as Drug Delivery Systems of RNAi in Cancer Therapy
por: Li, Diedie, et al.
Publicado: (2021)

Emerging Epigenetic‐Based Nanotechnology for Cancer Therapy: Modulating the Tumor Microenvironment
por: Zhang, Jiaxin, et al.
Publicado: (2023)

Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer
por: Li, Jiawei, et al.
Publicado: (2023)

Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy
por: Ma, Youzhao, et al.
Publicado: (2023)

Current and Emerging Therapies for HER2-Positive Women With Metastatic Breast Cancer
por: Porter, Karlyn, et al.
Publicado: (2017)

Emerging candidates in breast cancer stem cell maintenance, therapy resistance and relapse
por: Sharma, Bhawna, et al.
Publicado: (2011)

ASO Author Reflections: Impact of Ipsilateral Supraclavicular Lymph Node Dissection on Breast Cancer
por: Lv, Minhao, et al.
Publicado: (2021)

UBE2S and UBE2C confer a poor prognosis to breast cancer via downregulation of Numb
por: Guo, Yanjing, et al.
Publicado: (2023)

“The emerging role of capivasertib in breast cancer”
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer
por: Lin, Mingxi, et al.
Publicado: (2021)

Increased Expression of CD81 in Breast Cancer Tissue is Associated with Reduced Patient Prognosis and Increased Cell Migration and Proliferation in MDA-MB-231 and MDA-MB-435S Human Breast Cancer Cell Lines In Vitro
por: Zhang, Ning, et al.
Publicado: (2018)

Overcoming Therapy Resistance and Relapse in TNBC: Emerging Technologies to Target Breast Cancer-Associated Fibroblasts
por: Mollah, Farhana, et al.
Publicado: (2021)

The emerging role of WISP proteins in tumorigenesis and cancer therapy
por: Liu, Yi, et al.
Publicado: (2019)

Emerging Sonodynamic Therapy‐Based Nanomedicines for Cancer Immunotherapy
por: Yang, Yunrong, et al.
Publicado: (2022)

Celecoxib in breast cancer prevention and therapy
por: Li, Jieqing, et al.
Publicado: (2018)

FOXC1 in cancer development and therapy: deciphering its emerging and divergent roles
por: Yang, Zhi, et al.
Publicado: (2017)

Single‐Cell Mobility Analysis of Metastatic Breast Cancer Cells
por: Zhuang, Jialang, et al.
Publicado: (2018)

The emerging role of BET inhibitors in breast cancer
por: Andrikopoulou, A., et al.
Publicado: (2020)

Emerging nanomedicines for effective breast cancer immunotherapy
por: Bahreyni, Amirhossein, et al.
Publicado: (2020)

Metastatic Breast Cancer: Review of Emerging Nanotherapeutics
por: Dissanayake, Ranga, et al.
Publicado: (2023)

The Emerging Role of the Microbiota in Breast Cancer Progression
por: Bernardo, Giancarla, et al.
Publicado: (2023)

The emerging role of SPOP protein in tumorigenesis and cancer therapy
por: Song, Yizuo, et al.
Publicado: (2020)

Targeted Drug Delivery Systems for Curcumin in Breast Cancer Therapy
por: Huang, Mian, et al.
Publicado: (2023)

A study of clinical and molecular characteristics in bilateral primary breast cancer
por: Li, Bin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pq2g4hui1ime3o5m0ttc2qg2vk